SEATTLE, July 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Tuesday, August 3, 2010 at 4:30 p.m. ET to review second quarter financial results. Access to the discussion may be obtained as follows:
|
Time: |
4:30 PM ET / 1:30 PM PT |
|
|
Date: |
August 3, 2010 |
|
|
Dial-in: |
1-800-901-5247 (domestic) or +1-617-786-4501 (international); |
|
|
conference pass code: 32238437 |
||
|
Webcast: |
www.dendreon.com (homepage and investor relations section) |
|
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-286-8010 or +1-617-801-6888 for international callers; the conference ID number is 82853835. The replay will be available from 7:30 pm ET on Tuesday, August 3rd until 11:59 pm ET on Tuesday, August 10th. In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.
About Dendreon
Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com
SOURCE Dendreon Corporation